BONESUPPORT Expands CERAMENT Procedure Registry
BONESUPPORT expanded its 2014 injectable bone substitute registry to include 230 CERAMENT™ G procedures, as well as procedures involving the CERAMENT V...
Feb 02, 2016,
Orthobiologics
ORTHOFLASHAnika Responds to CINGAL’s Drug Classification
In late 2015, FDA assigned Anika Therapeutics' CINGAL to the Center for Drug Evaluation and Research (CDER) and not the...
Jan 25, 2016, Carolyn LaWell
AlloSource Receives Patent for ProChondrix Cartilage Repair Product
AlloSource was awarded U.S. Patent No. 9,186,253, Cartilage mosaic compositions and methods, for its ProChondrix® Cartilage Restoration Matrix allograft product....
Jan 19, 2016, Julie Vetalice
Bone Therapeutics Launches Phase IIA Study for Treatment of Multiple Fractures with ALLOB
Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy...
Jan 18, 2016, Julie Vetalice
20,000 Patients Treated with BONESUPPORT’s CERAMENT
BONESUPPORT announced the milestone of >20,000 patients treated worldwide to date with CERAMENT™ injectable drug-eluting bone substitute products....
Jan 11, 2016, Julie Vetalice
Bioventus Launches Durolane OA Treatment in Taiwan
Bioventus launched DUROLANE® single-injection hyaluronic acid-based osteoarthritis treatment in Taiwan....
Jan 04, 2016, Julie Vetalice
Vericel Submits BLA to FDA for MACI for Treatment of Knee Cartilage Defects
Vericel submitted a Biologics License Application to FDA for MACI™ matrix applied characterized autologous cultured chondrocytes, an investigational product intended...
Jan 04, 2016, Julie Vetalice
Loading new posts...
No more posts
